Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomised Phase II Study of Neoadjuvant BIBW 2992 Versus Herceptin Versus Lapatinib in Her2 Positive Breast Cancer Patients

NCT00826267 is registered in ClinicalTrials.gov with Boehringer Ingelheim as lead sponsor.

NCT NCT00826267
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00826267 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomised Phase II Study of Neoadjuvant BIBW 2992 Versus Herceptin Versus Lapatinib in Her2 Positive Breast Cancer Patients
Lead sponsor
Boehringer Ingelheim
Phase
Phase 2
Overall status
Completed
Start date
January 31, 2009
Completion date
Not reported
Enrollment
29 (actual)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

breast neoplasms